{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01111279",
      "orgStudyIdInfo": {
        "id": "BTT-gpASIT004"
      },
      "organization": {
        "fullName": "BioTech Tools S.A.",
        "class": "INDUSTRY"
      },
      "briefTitle": "Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis",
      "officialTitle": "Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis"
    },
    "statusModule": {
      "statusVerifiedDate": "2011-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2010-03"
      },
      "primaryCompletionDateStruct": {
        "date": "2010-09",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2010-11",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2010-04-20",
      "studyFirstSubmitQcDate": "2010-04-26",
      "studyFirstPostDateStruct": {
        "date": "2010-04-27",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2011-02-28",
      "lastUpdatePostDateStruct": {
        "date": "2011-03-01",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "oldNameTitle": "Thierry Legon / CEO",
        "oldOrganization": "BioTech Tools"
      },
      "leadSponsor": {
        "name": "BioTech Tools S.A.",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients."
    },
    "conditionsModule": {
      "conditions": [
        "Seasonal Allergic Rhinoconjunctivitis"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 27,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Biological: Placebo solution"
          ]
        },
        {
          "label": "gpASIT+TM",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: gpASIT+TM"
          ]
        },
        {
          "label": "gpASIT+TM/adjuvant",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Biological: gpAST+TM/adjuvant"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "gpASIT+TM",
          "description": "1 subcutaneous injection every 7 days, during 29 days.",
          "armGroupLabels": [
            "gpASIT+TM"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "gpAST+TM/adjuvant",
          "description": "1 subcutaneous injection every 7 days, during 29 days",
          "armGroupLabels": [
            "gpASIT+TM/adjuvant"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo solution",
          "description": "1 subcutaneous injection every 7 days, during 29 days",
          "armGroupLabels": [
            "Placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Clinical tolerability and safety of the treatment",
          "description": "The following parameters will be assessed : general physical status, vital signs, haematological parameters , general blood biochemistry parameters, all (serious) adverse, immunological analysis (total IgG, total IgE) and inflammatory parameters (CRP, sedimentation rate)",
          "timeFrame": "3 times during the treatment phase, at week 24 (the end of the study)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Impact of gpASIT+TM on the immunological status of the subjects",
          "description": "The following parameters will be assessed :\n\n* allergen-specific IgE, IgG, IgG4, IgA antibody concentrations,\n* adjuvant-specific IgG antibody concentrations,\n* lymphoproliferation and production of IL-10 in allergen and adjuvant stimulated PBMC.",
          "timeFrame": "visit 1, week 7, week 18 and week 24"
        },
        {
          "measure": "Impact of gpASIT+TM on the clinical status of the subjects",
          "description": "The following parameters will be assessed (during the pollen season following treatment):\n\n* daily average allergic symptom score,\n* daily average allergic medication score,\n* number of \"well-days\",\n* Visual Analogue Scale .",
          "timeFrame": "1 May - 15 August 2010"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject has given written informed consent\n* Age between 18 and 50 years\n* The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status\n* Male or non pregnant, non-lactating female\n* Females unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or post menopausal (defined as a minimum of one year since the last menstrual period))\n* Allergy diagnosis:\n\n  * A history of seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least during the two previous years\n  * A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture\n  * Specific IgE against grass pollen (RAST class 2 or IgE \\> 0.7 kU/l)\n  * Asymptomatic to perennial inhalant allergens even if shown to be hypersensitive in a skin prick test.\n\nExclusion Criteria:\n\n* Subjects with current or past immunotherapy (any time in the past)\n* A history of hypersensitivity to the excipients\n* Subjects requiring control medication against asthma (bronchodilator nebulised drugs or local or systemic corticosteroids)\n* Subjects with documented evidence of acute or significant chronic sinusitis (as determined by investigator)\n* Subjects with a history of hepatic or renal disease\n* Subjects symptomatic to perennial inhalant allergens\n* Subjects with rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative agent…)\n* Subject with malignant disease, autoimmune disease (and family medical history of autoimmune disease)\n* Any chronic disease, which may impair the subject's ability to participate in the trial (i.e. severe congestive heart failure, active gastric or duodenal ulcer, uncontrolled diabetes mellitus, etc…)\n* Subjects requiring beta-blockers medication\n* Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants)\n* Subject with febrile illness (\\> 37.5°C, oral)\n* A known positive serology for HIV-1/2, HBs antigen or anti-HCV antibodies\n* The subject is immunocompromised by medication or illness, has received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry\n* Receipt of blood or a blood derivative in the past 6 months preceding trial entry\n* Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 4 weeks preceding the trial\n* Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 1 week preceding the trial\n* Use of long-acting antihistamines\n* Female subjects who are pregnant, lactating, or of child-bearing potential and not protected from pregnancy by a sufficiently reliable method (OCs, IUD)\n* Any condition which could be incompatible with protocol understanding and compliance\n* Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship\n* Unreliable subjects including non-compliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give informed consent or to abide by the requirements of the protocol\n* Subjects without means of contacting the investigator rapidly in case of emergency, or not able to be contacted rapidly by the investigator\n* Participation in another clinical trial and/or treatment with an experimental drug within 1 month of trial start\n* Subjects who participated to trial BTT-gpASIT003 and were in the treated groups",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "50 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Jan Ceuppens, Professor",
          "affiliation": "UZ Leuven",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "UZ Leuven, Gasthuisberg",
          "city": "Leuven",
          "zip": "3000",
          "country": "Belgium",
          "geoPoint": {
            "lat": 50.87959,
            "lon": 4.70093
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    }
  },
  "hasResults": false
}